Compare STRIDES PHARMA SCIENCE with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs IPCA LABS - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE IPCA LABS STRIDES PHARMA SCIENCE/
IPCA LABS
 
P/E (TTM) x 16.3 31.8 51.2% View Chart
P/BV x 1.0 6.6 15.0% View Chart
Dividend Yield % 0.5 0.2 266.6%  

Financials

 STRIDES PHARMA SCIENCE   IPCA LABS
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
IPCA LABS
Mar-19
STRIDES PHARMA SCIENCE/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,1471,042 110.1%   
Low Rs642590 108.8%   
Sales per share (Unadj.) Rs317.2298.6 106.2%  
Earnings per share (Unadj.) Rs7.835.0 22.4%  
Cash flow per share (Unadj.) Rs25.149.4 50.7%  
Dividends per share (Unadj.) Rs2.003.00 66.7%  
Dividend yield (eoy) %0.20.4 60.8%  
Book value per share (Unadj.) Rs274.3247.1 111.0%  
Shares outstanding (eoy) m89.50126.35 70.8%   
Bonus/Rights/Conversions ESOPESOS-  
Price / Sales ratio x2.82.7 103.2%   
Avg P/E ratio x114.023.3 489.0%  
P/CF ratio (eoy) x35.716.5 216.3%  
Price / Book Value ratio x3.33.3 98.8%  
Dividend payout %25.58.6 297.4%   
Avg Mkt Cap Rs m80,058103,108 77.6%   
No. of employees `0002.513.4 18.7%   
Total wages/salary Rs m4,3417,874 55.1%   
Avg. sales/employee Rs Th11,325.82,807.0 403.5%   
Avg. wages/employee Rs Th1,731.4585.8 295.6%   
Avg. net profit/employee Rs Th280.1329.0 85.1%   
INCOME DATA
Net Sales Rs m28,39437,732 75.3%  
Other income Rs m941577 163.1%   
Total revenues Rs m29,33438,309 76.6%   
Gross profit Rs m3,9656,901 57.5%  
Depreciation Rs m1,5401,824 84.4%   
Interest Rs m1,962189 1,040.0%   
Profit before tax Rs m1,4035,465 25.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m971,042 9.3%   
Profit after tax Rs m7024,422 15.9%  
Gross profit margin %14.018.3 76.4%  
Effective tax rate %6.919.1 36.4%   
Net profit margin %2.511.7 21.1%  
BALANCE SHEET DATA
Current assets Rs m24,83623,778 104.5%   
Current liabilities Rs m18,99310,975 173.1%   
Net working cap to sales %20.633.9 60.6%  
Current ratio x1.32.2 60.4%  
Inventory Days Days71104 68.4%  
Debtors Days Days11366 172.0%  
Net fixed assets Rs m34,28920,368 168.3%   
Share capital Rs m895253 354.2%   
"Free" reserves Rs m23,65130,971 76.4%   
Net worth Rs m24,54631,224 78.6%   
Long term debt Rs m15,5131,409 1,101.4%   
Total assets Rs m65,43745,507 143.8%  
Interest coverage x1.730.0 5.7%   
Debt to equity ratio x0.60 1,401.1%  
Sales to assets ratio x0.40.8 52.3%   
Return on assets %4.110.1 40.2%  
Return on equity %2.914.2 20.2%  
Return on capital %6.917.3 39.8%  
Exports to sales %045.9 0.0%   
Imports to sales %016.6 0.0%   
Exports (fob) Rs mNA17,308 0.0%   
Imports (cif) Rs mNA6,266 0.0%   
Fx inflow Rs m15,69717,308 90.7%   
Fx outflow Rs m7356,266 11.7%   
Net fx Rs m14,96211,042 135.5%   
CASH FLOW
From Operations Rs m1,8714,923 38.0%  
From Investments Rs m5,826-1,563 -372.7%  
From Financial Activity Rs m-10,157-1,832 554.4%  
Net Cashflow Rs m-2,6151,528 -171.2%  

Share Holding

Indian Promoters % 27.7 45.9 60.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 11.4 331.6%  
FIIs % 8.6 25.3 34.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 17.4 148.9%  
Shareholders   56,241 36,892 152.4%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC LTD  

Compare STRIDES PHARMA SCIENCE With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Down 513 Points; Banking and Auto Stocks Witness Huge Selling(12:30 pm)

Share markets in India have extended early losses and are presently trading deep in the red.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

These 3 Recent Events Will Impact the Price of Gold(Fast Profits Daily)

Jul 1, 2020

Recent developments in the bullion market may put some short term pressure on gold prices.

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Jul 14, 2020 12:27 PM

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 8-QTR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS